Glycogen Storage Disease Type I
9
3
4
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 9 trials
100.0%
+13.4% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (9)
Diazoxide in the Treatment of Type 1 Glycogenosis
Early Check: Expanded Screening in Newborns
Use of Continuous Glucose Monitoring to Evaluate Postprandial Response to Raw Cornstarch Supplementation in Adult Glycogen Storage Disease Type I
Accuracy of Home Lactate Meter and Accu-chek Glucometer in Patients With Glycogen Storage Disease
Dietary Treatment Strategies and Metabolic Control in Glycogen Storage Disease Type I
The Use of Uncooked Sweet Manioc Starch to Treat Hepatic Glycogen Storage Diseases
Biomarker for Glycogen Storage Diseases (BioGlycogen)
Anaplerotic Therapy Using Triheptanoin for Patients With Glycogen Storage Disease Type I
Safety, Efficacy Evaluation of Empagliflozin Administration for Neutropenia in Glycogenosis Type 1b and G6PC3 Deficiency